Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

thyroid cancer

AstraZeneca AZ

AZ agrees to $320m deal for Zoladex

TerSera Therapeutics acquires rights to oncology drug in US and Canada

Lilly elects Prof Carolyn Bertozzi to board of directors

She brings oncology, inflammation and infection research expertise to the firm

- PMLiVE

FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

- PMLiVE

New guide to improve cancer control published in EU

Outlines recommendations to boost quality of life and reduce financial burden

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

Eli Lilly HQ

Lilly claims first place for JAK inhibitor Olumiant in EU

EMA approves once-daily rheumatoid arthritis drug ahead of Pfizer’s Xeljanz

- PMLiVE

Winning the war against cancer

Dr Josep Figueras on survival, access to treatments and the need for good data in oncology

- PMLiVE

Seattle Genetics signs $2bn deal for Immunomedics’ cancer drug

Buys rights to breast cancer drug candidate that could be be in line for FDA approval by year end

- PMLiVE

Dr Reddy’s brings its generics portfolio to France

Continues the European roll-out of its oncology and anti-infective products

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

- PMLiVE

Real-world evidence

Companies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links